

RealRate Inc., 2040 Martin Ave., Santa Clara, CA 95050



RealRate

July 10, 2026


To the CEO
Oncotelic Therapeutics
Inc
29397 AGOURA RD.
#107
AGUORA HILLS, CA 91301
USA

Oncotelic Therapeutics Inc TOP Rated in the US Pharmaceutical Ranking

Dear Sir or Madam,

at RealRate we have just published the 2026 US Pharmaceutical ranking. I am happy to inform you that Oncotelic Therapeutics Inc has been TOP Rated at rank 13 out of 178.

Overall, 178 US companies were analyzed with respect to their financial strength. The complete rating is published at <https://www.realrate.ai/rankings>. Your individual rating report, showing your strengths compared to your competitors is attached.



RealRate is an international rating agency based in Santa Clara and Berlin. We use artificial intelligence to create fair and explainable company ratings. Customers highly appreciate the RealRate rating seal: only the strongest companies are able to offer highly attractive and innovative products with top customer services. Billion dollar companies rely on our rating and build trust with their customers.

You too can acquire the RealRate seal and advertise with it. We only reach out to the top-rated companies, like yours and only those may subscribe for our seal. Save a lot of money and effort compared to traditional rating agencies: get a RealRate seal for just \$9,900. Simply sign the attached order form and send it back via email.

Please feel free to book a short video call with me: <https://calendly.com/holger-bartel>


Sincerely,

Dr. Holger Bartel, CEO

RealRate Seal Subscription

RealRate Inc.
2040 Martin Ave., Santa Clara, California 95050, USA
Via email to: holger.bartel@realrate.ai

We subscribe to the Pharmaceutical RealRate rating for Oncotelic Therapeutics Inc. The subscription comprises the annual rating update. The invoice will be sent annually, provided that a TOP rating is achieved again. The subscription can be cancelled by written letter, effective for the following year.



RealRate provides the rating seal as a scalable vector graphic. It can be used without any restrictions by Oncotelic Therapeutics Inc (Customer) for all promotional purposes, i.e. in product brochures, presentations, websites and broadcasting.

Item	2026 US Pharmaceutical RealRate rating seal for Oncotelic Therapeutics Inc
Amount	USD 9,900
Order no.	2026-0000908259

Amounts payable by Customer are exclusive of taxes. Customer is responsible for all his taxes and will pay such amounts invoiced by RealRate.

Billing address


Company name	Full name
Street address	Department
City	Phone number
State / province	Email address
ZIP code	
Country	

Shipping address

The electronic RealRate rating seal and the invoice will be sent to
Delivery email

Oncotelic Therapeutics Inc

Date, location, name



The relative strengths and weaknesses of Oncotelic Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncotelic Therapeutics Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 138% points. The greatest weakness of Oncotelic Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 86% points.

The company's Economic Capital Ratio, given in the ranking table, is 377%, being 148% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	1,198
Cost of Goods Sold	0
Intangible Assets	2,788
Liabilities, Current	18,143
Liabilities, Non-Current	0
Other Assets	389,102
Other Compr. Net Income	0
Other Expenses	111,550
Other Liabilities	113,213
Other Net Income	363,762
Other Revenues	0
Property and Equipment	0
Research and Development	4.4
Selling, General and Administrative Expense	3,182

Output Variable	Value in 1000 USD
Assets	393,088
Liabilities	131,357
Expenses	114,737
Revenues	0
Stockholders Equity	261,732
Net Income	249,025
Comprehensive Net Income	249,025
BaseVar	501,472
ECR before LimitedLiability	313%
Economic Capital Ratio	377%